Proteogenomics in Drug Development: Linking Genomic Data to Protein Quantification Workflows

Proteogenomics drug development workflows are closing the gap between what genomic data predicts and what proteins actually do, but most labs have not yet built the infrastructure to exploit these capabilities. Proteogenomics, the integration of genomic and proteomic data within a unified analytical framework, is reshaping how drug developers identify targets, characterize biologics, and validate protein expression across the full development pipeline. While genomics reveals what a biological system might do, quantitative proteomics reveals what it is actually doing, and bridging those two layers is increasingly where therapeutic decisions are made.

How proteogenomics advances drug development workflows

Proteogenomics in drug development extends conventional genomic analysis by incorporating protein-level quantification to provide a more complete view of cellular biology. Genomic variants, copy number alterations, and transcript abundance do not consistently predict protein levels due to post-transcriptional regulation, protein degradation rates, and post-translational modifications. Proteogenomic workflows address this gap by applying mass spectrometry-based proteomics to samples that have also been characterized at the genomic or transcriptomic level, then integrating the resulting data to identify proteins whose behavior cannot be predicted from sequence data alone.

In oncology drug development, this approach has proven particularly powerful. A review of cancer proteogenomics research, drawing on CPTAC studies across multiple tumor types, has shown that integrating proteomic and genomic profiles uncovers therapeutic targets and drug resistance mechanisms that genomic analysis alone cannot reveal. For drug developers working across other disease areas, the same logic applies: protein-level data contextualize genomic findings and prioritize targets based on what proteins are expressed, in what quantities, and in what modified states.

Drug target identification using proteogenomic data

Drug target identification in proteogenomics requires more than locating a genomic variant; it requires confirming that the encoded protein is expressed, accessible, and functionally relevant at the protein level. Proteogenomic workflows support this by integrating genomic and transcriptomic data with quantitative proteomics, a multiomics data integration approach that generates candidate target lists grounded in protein-level evidence rather than from sequence data alone. This multi-layer evidence base reduces the rate of late-stage failures driven by targets that appear genomically compelling but prove poorly expressed or post-translationally inactivated in the relevant tissue context.

Protein quantitative trait locus analysis, which maps genetic variants to variation in protein abundance, is an emerging component of drug target identification workflows. Recent large-scale studies have demonstrated that pQTL mapping using aptamer-based proteomics across population cohorts can identify causal protein mediators of disease with stronger mechanistic resolution than transcript-level equivalents. For drug developers, this means genetic associations identified in genome-wide studies can be interrogated at the protein level to confirm whether the implicated gene product is a tractable target.

Protein quantification strategies: DIA vs TMT labeling

Two mass spectrometry-based protein quantification approaches dominate proteogenomic workflows in drug development: DIA and tandem mass tag isobaric labeling. DIA systematically fragments all detectable peptides within defined mass windows, generating comprehensive peptide inventories from each run without requiring predefined targets. Tandem mass tag labeling chemically tags peptide samples before pooling them for simultaneous analysis, enabling multiplexed quantification of up to 18 samples in a single run.

Head-to-head benchmarking of the two approaches in drug target deconvolution contexts has found that tandem mass tag labeling identifies more peptides with lower inter-replicate variability, while DIA provides greater accuracy in identifying true drug targets and stronger dose-response correlation. The choice between approaches depends on experimental objectives: multiplexed comparative studies across large sample cohorts favor tandem mass tag labeling, while high-confidence target identification and structural proteomics applications favor DIA. Understanding this trade-off is essential for designing proteogenomic workflows that will produce defensible results at the target selection stage.

Table 1. Comparison of DIA and tandem mass tag labeling for proteogenomic protein quantification workflows.

Proteogenomics for protein expression validation in cell and gene therapy

Cell and gene therapy programs present protein quantification demands that conventional genomic characterization alone cannot satisfy. A viral vector or plasmid construct that is verified at the sequence level must also be confirmed to drive correct protein expression in the target cell population without generating unintended proteomic changes. Proteogenomic approaches address this need by combining genomic confirmation of construct integrity with quantitative proteomics to assess the expressed protein landscape following delivery.

In gene therapy drug development, quantitative proteomics is applied to confirm that the therapeutic transgene is expressed at appropriate levels and to detect any host cell protein responses to vector delivery. Mass spectrometry-based proteogenomics provides insight into therapeutic targets and resistance mechanisms by examining the proteomic consequences of genetic interventions, a capability that translates directly to evaluating cell and gene therapy constructs in development. For autologous cell therapy programs, where the product is manufactured from individual patient material, proteogenomic profiling also supports lot release by confirming consistent protein expression across patient-derived batches.

These analytical workflows connect naturally to analytical characterization platform strategies for viral vectors, where the goal is to characterize the expressed proteome as completely and accurately as possible before advancing a product through the development pipeline.

Multiomics data integration: Workflow challenges in drug development

Integrating genomic and proteomic datasets within a single drug development pipeline introduces substantial bioinformatic and practical complexity. The two data types differ in their dynamic range, quantification units, missing value patterns, and sensitivity to sample handling, which means that integrating them requires deliberate design at the experimental planning stage rather than retrospective data merging. Multiomics study design frameworks emphasize that batch effects introduced by processing samples on different days or using inconsistent sample preparation protocols will propagate across integrated datasets and confound downstream analysis.

Proteogenomic databases constructed from patient-derived sequencing data require custom search strategies that go beyond standard protein sequence databases. Novel peptides arising from somatic mutations, splice variants, or non-canonical open reading frames are invisible to conventional proteomics searches and must be identified by querying custom databases built from the corresponding genomic data. This requirement places bioinformatic infrastructure demands on laboratories that have not historically operated at the intersection of genomics and proteomics, and it is one of the primary reasons that proteogenomic workflows have been slower to scale into routine drug development practice than either platform individually.

Proteogenomics drug development: Translating data to clinical protein quantification

The translation of proteogenomic findings into clinical drug development requires protein quantification assays that can operate at higher throughput and with greater harmonization than discovery-phase mass spectrometry workflows typically provide. Targeted mass spectrometry approaches were specifically developed to bridge the gap between proteogenomic discovery and clinical validation by providing multiplexed, precise protein quantification with the dynamic range needed to measure low-abundance targets in complex clinical samples.

Quantitative proteomics in translational contexts, including absorption, distribution, metabolism, and excretion studies that rely on protein-level quantification of drug-metabolizing enzymes and transporters, has established the methodological precedents that proteogenomic workflows are now adapting for broader drug development applications. The convergence of these approaches, as laboratories build integrated pipelines that move from genomic drug target identification through mass spectrometry-based confirmation to clinical assay deployment, represents the operational vision that drives investment in proteogenomics infrastructure.

Integrating proteogenomics across the drug development pipeline

Proteogenomics drug development workflows are most valuable when applied consistently across the full pipeline, from early drug target identification through clinical biomarker qualification, rather than in isolated discovery experiments. Their practical contribution lies in providing protein-level confirmation of what genomic data predicts and flagging the frequent discrepancies between transcript abundance and functional protein expression. Linking drug development process analytics to proteogenomic characterization workflows creates a more complete evidence base for advancing candidates with confidence.

Laboratories that build the bioinformatic infrastructure and multiomics sample preparation capabilities to support proteogenomic protein quantification are positioning themselves to generate richer, more actionable data at every stage of the pipeline. As mass spectrometry platforms continue to improve in sensitivity and throughput, and as computational tools for multiomics integration mature, the cost and complexity barriers that have limited proteogenomics to specialized centers are steadily falling. The result is a widening access to a process analytical technology framework within which genomic and proteomic data are treated as complementary, not parallel, sources of drug development intelligence.

This content includes text that has been created with the assistance of generative AI and has undergone editorial review before publishing. Technology Networks' AI policy can be found here.